Leppik R A, Mynett A, Lazareno S, Birdsall N J
National Institute for Medical Research, The Ridgeway, Mill Hill, London, United Kingdom.
Mol Pharmacol. 2000 Mar;57(3):436-45. doi: 10.1124/mol.57.3.436.
It has been demonstrated previously that amilorides can interact with a well defined allosteric site on the human alpha(2A)-adrenergic receptor. In this study, the question was explored as to whether the human alpha(1A)-adrenergic receptor also possesses an equivalent allosteric site. The six amilorides examined strongly increased the dissociation rate of the antagonist [(3)H]prazosin from the alpha(1A)-adrenergic receptor in a concentration-dependent manner. With the parent amiloride, the dissociation data were well fitted by an equation derived from the ternary complex allosteric model, compatible with amiloride acting at a defined allosteric site on the alpha(1A)-adrenergic receptor. In contrast, the dissociation data for [(3)H]prazosin in the presence of the amiloride analogs were not compatible with the equation derived from a one-allosteric-site model, but could be fitted well by an equation derived from a two-allosteric-site model. However, certain individual parameters could not be resolved. The observed dissociation rate constants increased steeply with increasing amiloride analog concentration, and in some cases the data could be fitted with a logistic equation. The slope factors calculated from such fits were 1.2 to 2.1. It is concluded that the structure-binding relationships of the amilorides at the alpha(1A)- and alpha(2A)-adrenergic receptors are different. The interactions of the five amiloride analogs, but not the parent amiloride, with the alpha(1A)-adrenergic receptor are compatible with the presence of two (but not one) allosteric sites, and is thus more complex than that found for the alpha(2A)-adrenergic receptor.
先前已证明,阿米洛利可与人类α(2A)-肾上腺素能受体上一个明确的变构位点相互作用。在本研究中,探讨了人类α(1A)-肾上腺素能受体是否也具有等效的变构位点这一问题。所检测的六种阿米洛利以浓度依赖性方式显著增加了拮抗剂[(3)H]哌唑嗪从α(1A)-肾上腺素能受体的解离速率。对于母体阿米洛利,解离数据可很好地用源自三元复合物变构模型的方程拟合,这与阿米洛利作用于α(1A)-肾上腺素能受体上一个明确的变构位点相符。相比之下,在阿米洛利类似物存在下[(3)H]哌唑嗪的解离数据与源自单变构位点模型的方程不相符,但可很好地用源自双变构位点模型的方程拟合。然而,某些个体参数无法解析。观察到的解离速率常数随阿米洛利类似物浓度增加而急剧增加,在某些情况下数据可用逻辑方程拟合。由此拟合计算出的斜率因子为1.2至2.1。得出结论,阿米洛利在α(1A)-和α(2A)-肾上腺素能受体上的结构-结合关系不同。五种阿米洛利类似物而非母体阿米洛利与α(1A)-肾上腺素能受体的相互作用与存在两个(而非一个)变构位点相符,因此比在α(2A)-肾上腺素能受体上发现的情况更复杂。